Communiqués de presse
Le journal des biotechs
Carmat, Celyad, Hybrigenics, entretien avec Jesús Martin-Garcia, DG de Geneuro
pHERV-W envelope protein fuels microglial cell-dependent damage of myelinated axons in multiple sclerosis
PNAS, July 23, 2019
A High-dose Pharmacokinetic Study of a New IgG4 Monoclonal Antibody Temelimab/GNbAC1 Antagonist of an Endogenous Retroviral Protein pHERV-W Env
Clinical Therapeutics, July 13, 2019
https://www.clinicaltherapeutics.com/article/S0149-2918(19)30296-6/pdf
ECTRIMS 2109 – Neuroprotective effects of temelimab in relapsing-remitting MS patients extend to 96 weeks
Phase IIb safety and efficacy data on temelimab at week 96 from the ANGEL-MS study
Neural Cell Responses Upon Exposure to Human Endogenous Retroviruses
Frontiers in Genetics, July 11, 2019
https://www.frontiersin.org/articles/10.3389/fgene.2019.00655/full
Variation in proviral content among human genomes mediated by LTR recombination
Rescuing the negative impact of human endogenous retrovirus envelope protein on oligodendroglial differentiation and myelination
Glia, November 14, 2018
https://geneuro.ch/data/news/2018-11-Go-ttle-et-al.-GLIA.pdf
GNbAC1 shows efficacy on MRI measures of neurodegeneration in relapsing-remitting MS patients over 48 weeks
Robert Glanzman at the 26th Annual Meeting of the European Charcot Foundation (November 2018) in Baveno, Italy
HERV-W-Env involvement in human T1D pathogenesis
S. Levet, J. Joanou, N. Queruel, J.Pierquin & H. Perron
https://geneuro.ch/data/news/18-05-22-Poster-ADA-2018-V2.pdf
A new therapeutic approach for type 1 diabetes: Rationale for GNbAC1, an anti‐HERV‐W‐Env monoclonal antibody
Diabetes, Obesity and Metabolism, May 10, 2018
CNNMoney interview
What’s the best strategy for Swiss Biotech Start-Ups?
Le Revenu TV – «Servier pourrait licencier un produit de Geneuro»
Le PDG de la biotech franco-suisse a expliqué au Revenu TV pourquoi les résultats mitigés de son GNbAC1 dans une forme de sclérose en plaques n’empêchent pas forcément la poursuite de son développement clinique. Il est aussi revenu sur le parcours boursier de la société, très chahuté en 2017.